México ¿cómo vamos? urges North American pharmaceutical cluster
North America requires a dedicated regional pharmaceutical cluster to insulate its supply chains against future global health emergencies, according to an analysis released in September by the organization México ¿Cómo vamos? The policy document highlights that while the global pharmaceutical market reached 1.77 billones de dólares in 2025, North America consumed 42% of that total, representing 740 mil millones de dólares, with the United States alone accounting for 520 mil millones de dólares.
- North America accounts for 42% of global pharmaceutical consumption, totaling 740 mil millones de dólares in 2025.
- Canada supplied 2.6 % and Mexico just 0.4 % of U.S. pharmaceutical import market shares by the second quarter of 2026.
- México ¿Cómo vamos? urges a transition toward regional coproductions for critical active pharmaceutical ingredients rather than chasing total self-sufficiency.
The stark disparity in regional pharmaceutical sourcing contrasts sharply with medical devices. By the second quarter of 2026, Canada supplied 2.6 % of U.S. pharmaceutical import market shares, while Mexico provided a negligible 0.4 %. Conversely, five European economies—Ireland, Germany, Switzerland, Belgium, and Italy—jointly supplied more than half of those same U.S. pharmaceutical imports. Meanwhile, the medical device sector exhibits much higher cross-border integration. The 2026 medical device market is estimated at 605 mil millones de dólares, with the United States concentrating 210 mil millones de dólares, and Mexico and Canada 20 mil millones de dólares.
The COVID-19 pandemic exposed systemic vulnerabilities inherent in relying on distant, highly concentrated healthcare supply chains. México ¿Cómo vamos? asserts that regional economic security extends beyond agroindustry and artificial intelligence infrastructure to encompass essential therapeutics and medical hardware. The policy framework emphasizes that the objective is not complete self-sufficiency, but rather the strategic identification of critical drugs, active ingredients, and basic supplies requiring localized manufacturing capacity. Achieving this balance depends on reducing extreme import dependence while preserving market asequibility and industrial competitiveness.
Complementary industrial capacities already exist across the three T-MEC nations. The United States maintains a strong research and development platform, Canada possesses advanced clinical research capabilities, and Mexico contributes specialized manufacturing infrastructure alongside a qualified workforce suited for trans-border production networks.
Future stability in regional healthcare delivery hinges on transitioning from fragmented purchasing to coordinated co-production models. By using established cross-border medical device specializations, the region can systematically secure its pharmacological pipeline against external shocks.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*